EMA Probe Into Suicide Risk With Liraglutide & Semaglutide Extended To Other GLP-1 Receptor Agonists

 
• By Neena Brizmohun

So far authorities have retrieved and are analyzing about 150 reports of possible cases of self-injury and suicidal thoughts, the European Medicines Agency said today.

drug label
Suicidal behaviour is not listed as a side effect in the EU product information for any GLP-1 receptor agonists • Source: Shutterstock

More from Europe

More from Geography